A novel Ca/P-containing mesoporous silica-based xerogels (CaMSX) with good degradability and low heat generation were synthesized for hemorrhage control by a modified sol-gel process and physicochemically characterized. The mesoporous silica-based xerogels without Ca/P (MSX) was also prepared as comparison. The in vitro whole blood coagulation time, activated partial thromboplastin time (APTT) and prothrombin time (PT) of the CaMSX were measured with MSX, Chinese traditional medicin-Yunnan medical powder (YM) and traditional zeolite. In vivo bleeding model was tested with rabbit’ ear side veins. The results illustrated that the CaMSX could remarkably promote the intrinsic and extrinsic blood coagulation processes which greatly depend on the dosage and the content of Ca in the CaMSX. The CaMSX had better efficiency in promoting coagulation process than that of MSX, YM and zeolite.

Background Randomized controlled trials (RCTs) have shown the efficacy and safety of Roxadustat and conclude that it has the potential to change the treatment for anemia associated with chronic kidney disease. However, the experience of its use from clinical perspectives post-approval is lacking. Aim Using a clinical practice context, this study aims to compare Roxadustat's effectiveness and tolerability with Erythropoietin (EPO) in patients with renal anemia undergoing dialysis. Methods We examined the clinical records of patients with a diagnosis of renal anemia on dialysis who were prescribed Roxadustat or Erythropoietin at the department of nephrology of the First Affiliated Hospital of Gannan Medical University from January 2021 to December 2021. Eligible hemodialysis (HD) or peritoneal dialysis (PD) patients with renal anemia, aged >18 or <75 years, without infection, active bleeding, and malignancy were recruited. These patients received Roxadustat or EPO based on the preferential prescription choice made by the nephrologists of the department. We retrospectively attempted to determine the treatment response measured by the change in hemoglobin rate, from baseline up to six months. We also explored the impact of various factors on the treatment response and reported adverse events. Results A total of 106 patients have been included in the final analysis, with 53 patients in each group. The mean age of the study group was 49.9 ± 13.6 years with the main Hb level at the baseline of 8.1 g/dL ± 1.23 g/dl. The gain of hemoglobin from the baseline averaged over six months was 2.2 ± 2.11 g/dl in the Roxadustat group compared with 1.1 ± 1.67 g/dL in the EPO group ( p=0.01 ) . As compared to EPO,Roxadustat reduced the total cholesterol level by -0.59 ± 1.08 mmol/l versus -0.01 ± 1.28 mmol/l ( p=0012 ) and the low-density lipoprotein (LDL) cholesterol by -0.48 ± 1.07 mmol/l versus -0.47 ± 1.05 ( p=0.017 ) in the first three months. Associated factors with a non-response to treatment were age greater than 65 years (OR=6, 95% CI: 1.23-32.46, p=0.02 ), hypertension (OR=3.5, 95%CI: 0.89-13.25, p=0.060 ), and heart failure (OR=4.18, 95%CI:4.18 1.04-20.39, p=0.040 ). Although the proportion of hospitalization and infection was higher in the EPO group and the incidences of gastrointestinal symptoms (vomiting, nausea) and blood transfusions were higher in the Roxadustat group, there were no statistically significant differences. Conclusion Roxadustat improved hemoglobin compared to erythropoietin in patients undergoing dialysis with a safe profile but precautions should be taken for old patients with a cardiovascular medical history.

A novel method is proposed to modify montmorillonite with coupling agents and Hexadecyl triphenyl phosphonium bromide surfactants made by our group (named P-surfactant in the following). The structure of organophilic montmorillonite (OMMT) was investigated by FT-IR, XRD and TG. The FT-IR shows the coupling agents were inserted between the layers of MMT and reacted with –OH of MMT. The results of X-ray diffraction shows that the coupling agents were all intercalated into the layers of MMT. The interlayer spacing of montmorillonite increases to 4.00 nm, the effect of modification is well. The results of TG showed the thermal stability was better.

A new mesoporous silica xerogel used as biodegradable material was synthesized by improved sol-gel methods. The xerogel’s degradation character and property of releasing character for bone morphological protein (BMP)were modified by adding calcium (Ca) and phosphor (P) elements into pure silica xerogel, and uesing sintering processes, as well as adding magnesium (Mg) into silica xerogel. The differential thermal and thermogravimetric analysis (DTA-TG), X-Ray diffraction analysis(XRD), Fourier infrared spectrum analysis (FITR), N2 adsorption-desorption analysis, Scanning electron microscope(SEM) and Transmitting electron microscope (TEM) observation were used to measure the thermal effects, crystalline state, pore diameter and specific surface area, surface morphology and inner structure of the xerogels. The xerogel’s degradability and BMP release were studied by simulated body fluid (SBF) immersion. The results indicated that the synthesized xerogels were mesoporous structure with pore diameter around 3 nm and the big specific surface area about 1000 m2/g.They were non crystall with hydroxyl and micro-molecular silica-oxygen groups. Xerogels dried at low sintering temperature degraded completely in 42 days in bursting manner and degraded in linear curves with sintering temperature increased as well as adding calcium and magnesium into xerogels. The BMP release behaviour from the Mg-xerogel dried naturally was in controlled manner.